Oral pH-triggered colon-specific ketoprofen loaded microspheres for the better management of early morning symptoms associated with rheumatoid arthritis. Part II: Pharmacokinetic and pharmacodynamic assessment in rats
{"title":"Oral pH-triggered colon-specific ketoprofen loaded microspheres for the better management of early morning symptoms associated with rheumatoid arthritis. Part II: Pharmacokinetic and pharmacodynamic assessment in rats","authors":"Krishna Sanka , Prabhakar Reddy Veerareddy , Rajeswara Rao Pragada","doi":"10.1016/j.jhip.2025.03.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the effectiveness of oral pH-triggered colon-specific ketoprofen-loaded microspheres (C-SKLMs) in managing early morning symptoms of rheumatoid arthritis (RA) through pharmacokinetic and pharmacodynamic assessments.</div></div><div><h3>Methods</h3><div>Pharmacokinetic parameters, including T<sub>max</sub>, C<sub>max</sub>, and mean residence time (MRT), were analyzed in animals treated with C-SKLMs and compared with pure ketoprofen. Pharmacodynamic evaluations assessed the ability of C-SKLMs to address early morning RA symptoms effectively by aligning drug release with the body's circadian rhythm.</div></div><div><h3>Results</h3><div>The T<sub>max</sub> for the C-SKLMs group (9.33 ± 1.63 h) was significantly prolonged compared to pure ketoprofen (2 h), indicating delayed drug release tailored to circadian needs. The C<sub>max</sub> for C-SKLMs (5.94 ± 1.20 μg/mL) was lower than that of pure ketoprofen (12.4 ± 3.00 μg/mL), demonstrating a controlled-release profile. Additionally, the MRT for C-SKLMs (12.96 ± 1.42 h) was approximately 1.4 times longer than for pure ketoprofen (9.44 ± 0.69 h), emphasizing extended drug release. Pharmacodynamic evaluations supported the superior effectiveness of C-SKLMs in managing early morning RA symptoms compared to pure ketoprofen.</div></div><div><h3>Conclusion</h3><div>C-SKLMs demonstrated significant potential to improve the management of early morning symptoms associated with RA through controlled, extended, and circadian-tailored drug release, making them a promising therapeutic approach.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 83-90"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Holistic Integrative Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S270736882500007X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To evaluate the effectiveness of oral pH-triggered colon-specific ketoprofen-loaded microspheres (C-SKLMs) in managing early morning symptoms of rheumatoid arthritis (RA) through pharmacokinetic and pharmacodynamic assessments.
Methods
Pharmacokinetic parameters, including Tmax, Cmax, and mean residence time (MRT), were analyzed in animals treated with C-SKLMs and compared with pure ketoprofen. Pharmacodynamic evaluations assessed the ability of C-SKLMs to address early morning RA symptoms effectively by aligning drug release with the body's circadian rhythm.
Results
The Tmax for the C-SKLMs group (9.33 ± 1.63 h) was significantly prolonged compared to pure ketoprofen (2 h), indicating delayed drug release tailored to circadian needs. The Cmax for C-SKLMs (5.94 ± 1.20 μg/mL) was lower than that of pure ketoprofen (12.4 ± 3.00 μg/mL), demonstrating a controlled-release profile. Additionally, the MRT for C-SKLMs (12.96 ± 1.42 h) was approximately 1.4 times longer than for pure ketoprofen (9.44 ± 0.69 h), emphasizing extended drug release. Pharmacodynamic evaluations supported the superior effectiveness of C-SKLMs in managing early morning RA symptoms compared to pure ketoprofen.
Conclusion
C-SKLMs demonstrated significant potential to improve the management of early morning symptoms associated with RA through controlled, extended, and circadian-tailored drug release, making them a promising therapeutic approach.